Extrafine triple therapy shows improved efficacy compared to ICS/LABA in a mouse model of asthma

D. Miglietta (Parma (PR), Italy), A. Pisano (Parma (PR), Italy), A. Allen (Parma (PR), Italy), D. Fragni (Parma (PR), Italy), G. Federico (Parma (PR), Italy), F. Bignami (Parma (PR), Italy), E. Zambelli (Parma (PR), Italy), R. Zecchi (Florence (FI), Italy), F. Boscaro (Florence (FI), Italy), B. Pioselli (Parma (PR), Italy), V. Mileo (Parma (PR), Italy), M. Civelli (Parma (PR), Italy), G. Villetti (Parma (PR), Italy)

Source: International Congress 2022 – In vivo and in vitro studies of airway diseases

Session: In vivo and in vitro studies of airway diseases
Session type: Thematic Poster
Number: 3166

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Miglietta (Parma (PR), Italy), A. Pisano (Parma (PR), Italy), A. Allen (Parma (PR), Italy), D. Fragni (Parma (PR), Italy), G. Federico (Parma (PR), Italy), F. Bignami (Parma (PR), Italy), E. Zambelli (Parma (PR), Italy), R. Zecchi (Florence (FI), Italy), F. Boscaro (Florence (FI), Italy), B. Pioselli (Parma (PR), Italy), V. Mileo (Parma (PR), Italy), M. Civelli (Parma (PR), Italy), G. Villetti (Parma (PR), Italy). Extrafine triple therapy shows improved efficacy compared to ICS/LABA in a mouse model of asthma. 3166

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.